Exhibitors Search
MolGenBio Co., Ltd.
Booth no.
E41
| Exhibition | PARTNERING |
|---|---|
| Country | Korea, South |
| Address | 1 Gwanak-ro, Gwanak-gu, Seoul, Republic of Korea |
| Tel (Rep.) | 02-6332-1004 |
| Website | http://molgenbio.com |
Company Introduction
MolGenBio is developing a novel proprietary synthetic biology platform technology targeting intractable diseases such as neurodegenerative diseases and cancer. Our innovative and robust platform technology aims to develop the first/best-in-class small molecule therapeutics by harnessing the expertise in microbial genome scanning, editing and assembly.
Our proprietary MTG (Molecule Through Gene) platform enables us to generate structural derivatives of small molecule drug candidates that are difficult to synthesize through the conventional medicinal chemistry approach.
Our CEO/founder Prof Yoon at Seoul National University elucidated the complete biosynthetic pathway of FK506 for the first time.
MolGenBio team has world-class expertise in tacrolimus R&D/manufacturing.
Our proprietary MTG (Molecule Through Gene) platform enables us to generate structural derivatives of small molecule drug candidates that are difficult to synthesize through the conventional medicinal chemistry approach.
Our CEO/founder Prof Yoon at Seoul National University elucidated the complete biosynthetic pathway of FK506 for the first time.
MolGenBio team has world-class expertise in tacrolimus R&D/manufacturing.
Promotional video
Exhibit Item
MolGenBio is developing a novel proprietary synthetic biology platform technology targeting intractable diseases such as neurodegenerative diseases and cancer. Our innovative and robust platform technology aims to develop the first/best-in-class small molecule therapeutics by harnessing the expertise in microbial genome scanning, editing and assembly. Our proprietary MTG (Molecule Through Gene) platform enables us to generate structural derivatives of small molecule drug candidates that are difficult to synthesize through the conventional medicinal chemistry approach. Our CEO/founder Prof Yoon at Seoul National University elucidated the complete biosynthetic pathway of FK506 for the first time. MolGenBio team has world-class expertise in tacrolimus R&D/manufacturing.
Exhibit Item Images
-
Product Name : Development of microbe-derived small molecules with novel therapeutic value via synthetic biology-based structure modifications.MG-TA205 ▷ A novel disease-modifying small molecule with neural regeneration-based combinatorial effects to target neurodegenerative diseases such as Alzheimer’s Disease & Parkinson’s Disease ▷ Robust activation of neural regeneration ▷ Inhibition of toxic protein aggregates (eg. α-synuclein, amyloid-β, tau) ▷ Inhibition of neuroinflammation
Exhibit Description
MG-TA205 ▷ A novel disease-modifying small molecule with neural regeneration-based combinatorial effects to target neurodegenerative diseases such as Alzheimer’s Disease & Parkinson’s Disease ▷ Robust activation of neural regeneration ▷ Inhibition of toxic protein aggregates (eg. α-synuclein, amyloid-β, tau) ▷ Inhibition of neuroinflammation
Co-Exhibitor or
Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.